Physician profile
Fawn Jin
NPI 1467557603
$1,468.11
in general payments reported to CMS, 2019-2025
19 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $61.11 · 2021: $97.33 · 2022: $122 · 2023: $292 · 2024: $205 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $401.20 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $211.96 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $165.64 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $146.17 | 2019-2023 | |
| Astellas Pharma US INC | $130.47 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $67.12 | 2019-2024 | |
| Lilly USA, LLC | $62.03 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.12 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $29.84 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Otsuka America Pharmaceutical, INC. | $29.45 | 2023-2024 | Rexulti |
| Daiichi Sankyo INC. | $29.15 | 2022-2023 | Injectafer |
| Boston Scientific Corporation | $24.05 | 2022 | |
| Abbott Laboratories | $22.12 | 2024 | Freestyle Libre 3 |
| Impel Pharmaceuticals INC. | $19.99 | 2023 | Trudhesa |
| Xeris Pharmaceuticals, INC. | $18.58 | 2024 | Gvoke Hypopen |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17.81 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.68 | 2020 | |
| Dynavax Technologies Corporation | $16.99 | 2024 | Heplisav-B |
| Exact Sciences Corporation | $13.74 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fawn Jin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.